Canada markets open in 8 hours 6 minutes

Geron Corporation (GERN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.3000-0.0800 (-3.36%)
At close: 04:00PM EDT
2.2800 -0.02 (-0.87%)
After hours: 07:52PM EDT

Geron Corporation

919 East Hillsdale Boulevard
Suite 250
Foster City, CA 94404
United States
650 473 7700
https://www.geron.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees69

Key Executives

NameTitlePayExercisedYear Born
Dr. John A. Scarlett M.D.Chairman, Pres & CEO1.26MN/A1951
Ms. Olivia Kyusuk BloomExec. VP of Fin., CFO & Treasurer743.27kN/A1969
Dr. Andrew J. GrethleinExec. VP & COO767.28kN/A1964
Ms. Melissa A. Kelly BehrsExec. VP of Bus. Operations & Chief Alliance Officer753.22kN/A1964
Mr. Anil KapurExec. VP of Corp. Strategy & Chief Commercial Officer654.89kN/A1970
Ms. Aron FeingoldVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Stephen N. Rosenfield J.D.Exec. VP, Chief Legal Officer & Corp. Sec.N/AN/A1950
Ms. Shannon OdamVP of HRN/AN/AN/A
Mr. Edward E. KovalExec. VP & Chief Bus. OfficerN/AN/A1962
Dr. Faye Feller M.D.Exec. VP & Chief Medical OfficerN/AN/A1982
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Corporate Governance

Geron Corporation’s ISS Governance QualityScore as of October 1, 2022 is 6. The pillar scores are Audit: 7; Board: 3; Shareholder Rights: 7; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.